Pegsiticase has shown the ability to efficiently reduce plasma uric acid levels in gout patients in successful U.S. Phase 1 clinical tests. The exclusive license enables Selecta to
Pharma Technology Focus’ digital magazine brings together the latest news from the pharmaceutical industry, as well as offering expert views and analysis from industry insiders to ensure the
Critical Outcome Technologies president and CEO Dr Wayne Danter said that receiving the Orphan Drug Designation for COTI-2 speaks to the need for new treatment options for patients
OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev (previously known as ColoAd1) in platinum-resistant ovarian cancer patients at
These settlements dismiss a pending appeal with the US Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be
The Class 1 resubmission follows a complete response letter issued by the FDA that referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured.
Sucampo CEO Peter Greenleaf said that with more than eight million prescriptions dispensed globally over the past eight years, Amitiza has demonstrated to be an effective treatment option
The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and position Pfizer in closer proximity to leading academic institutions, hospitals and patient
The purchase order is for AllStar Health Brands’, TapouT Muscle Recovery Pain Relief, Muscle Growth Supplement and TapouT Muscle Post Recovery Supplement. The purchase order marks AllStar’s continued
This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen’s intellectual property portfolio for pluripotent
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.